Core Concepts
Celiac disease is a common, chronic, and complex autoimmune disorder caused by intolerance to gluten, with a wide spectrum of clinical manifestations and an increasing global prevalence that may be linked to environmental factors. While a gluten-free diet is the only current treatment, it poses significant challenges, leading to the development of novel therapeutic options.
Abstract
The content provides a comprehensive overview of celiac disease, covering several key aspects:
Rising Prevalence and Environmental Factors:
Celiac disease was once thought to be a rare childhood condition, but its prevalence has increased significantly over the past several decades, with a global pooled prevalence of 1.4% as of 2018.
The rise in celiac disease is consistent with the growth of other autoimmune disorders, suggesting that shared environmental factors, such as migration, dietary changes, and altered wheat consumption, may be playing a role as triggers.
Diagnosis and No-Biopsy Approach:
Celiac disease is often underdiagnosed or misdiagnosed, with an estimated 60 million people worldwide affected but undiagnosed.
Serological testing for specific antibodies is central to screening, and a no-biopsy approach for diagnosis has been established in pediatric patients and is showing promise for adults.
Associated Life-Threatening Conditions:
Celiac disease is associated with several other gastrointestinal conditions, such as inflammatory bowel disease and functional GI disorders, as well as non-GI conditions, including osteopenia, women's health disorders, certain forms of cancer, and cardiomyopathy.
Gluten-Free Diet Challenges:
A gluten-free diet is the only treatment for celiac disease, but it poses significant physical, psychological, social, and financial challenges for patients.
Adherence to a gluten-free diet does not always result in complete mucosal recovery, and it can lead to nutrient imbalances and the risk of cross-contamination.
Emerging Therapies:
The limitations of the gluten-free diet have driven the development of novel therapeutic interventions, including agents that modulate the immunostimulatory effects of toxic gluten peptides, eliminate these peptides before they reach the intestine, induce gluten tolerance, and restore gut microbiota balance.
Several promising therapies are in clinical and preclinical development, though none have yet reached phase 3 testing.
Stats
The pooled global prevalence of celiac disease was 1.4% as of 2018.
Incidence of celiac disease has increased by as much as 7.5% annually over the past several decades.
It is estimated that almost 60 million people worldwide have celiac disease, but most remain undiagnosed or misdiagnosed.
In children, mucosal recovery is achieved in 95% within 2 years of adopting a gluten-free diet, while in adults, only 34% and 66% achieve it within 2 and 5 years, respectively.
Quotes
"Gluten was first identified as the cause of celiac disease in the 1950s. At that time, the condition was thought to be a relatively rare GI disease of childhood that primarily affected people of European descent, but it is now known to be a common disease affecting those of various ages, races, and ethnicities."
"Emerging data indicate that gastroenterologists should be vigilant in screening patients with celiac disease for several other GI conditions."
"Adherence to GFD does not always equate to complete mucosal recovery. While mucosal recovery is achieved in 95% of children within 2 years of the diet's adoption, only 34% and 66% of adults obtain it within 2 and 5 years, respectively."